National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.

Rapid Review

Commenced Completed Outcome
June 2010 22/06/2010 Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.